COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir/ritonavir is co-prescribed

被引：0
作者：
Nadir Yalcin
Karel Allegaert
机构：
[1] Hacettepe University,Department of Clinical Pharmacy, Faculty of Pharmacy
[2] Erasmus MC,Department of Clinical Pharmacy
[3] KU Leuven,Department of Pharmaceutical and Pharmacological Sciences
[4] KU Leuven,Department of Development and Regeneration
来源：
European Journal of Clinical Pharmacology | 2022年 / 78卷
关键词：
SARS-CoV-2; Seizure; Anticonvulsants; Nirmatrelvir; Ritonavir; Dosing; Drug interaction;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Management and dose adjustment are a major concern for clinicians in the absence of specific clinical outcome data for patients on antiepileptic drugs (AEDs), in the event of short-term (5 days) nirmatrelvir/ritonavir co-exposure. Therefore, in this report, we identified drugs that require dose adjustment because of drug-drug interactions (DDIs) between nirmatrelvir/ritonavir and AEDs. We hereby used four databases (Micromedex Drug Interaction, Liverpool Drug Interaction Group for COVID-19 Therapies, Medscape Drug Interaction Checker, and Lexicomp Drug Interactions) and DDI-Predictor.
引用
收藏
页码：1697 / 1701
页数：4
相关论文
共 72 条
  • [1] Chiu MN(2022)Safety profile of COVID-19 drugs in a real clinical setting Eur J Clin Pharmacol 78 733-753
  • [2] Bhardwaj M(2022)Using nirmatrelvir/ritonavir in patients with epilepsy: an update from the Israeli chapter of the International League Against Epilepsy Epilepsia 94 1766-1767
  • [3] Sah SP(2022)In the age of Omicron variant: Paxlovid raises new hopes of COVID-19 recovery J Med Virol 5 257-263
  • [4] Noyman I(2016)A comparison of five common drug-drug interaction software programs regarding accuracy and comprehensiveness J Res Pharm Pract 9 215-236
  • [5] Ekstein D(2010)Membrane transporters in drug development Nat Rev Drug Discov 8 296-307
  • [6] Fahoum F(2019)Physiologically-based pharmacokinetic models for CYP1A2 drug-drug interaction prediction: a modeling network of fluvoxamine, theophylline, caffeine, rifampicin, and midazolam CPT Pharmacometrics Syst Pharmacol 194 E218-51
  • [7] Herskovitz M(2022)Nirmatrelvir-ritonavir for COVID-19 CMAJ 181 47-150
  • [8] Linder I(2022)Prescribing nirmatrelvir-ritonavir: how to recognize and manage drug-drug interactions Ann Intern Med 40 147-undefined
  • [9] Ben Zeev B(2005)The role of genetics and ethnicity in epilepsy management Acta Neurol Scand Suppl 174 undefined-undefined
  • [10] Eyal S(2006)Possible interaction between lopinavir/ritonavir and valproic acid exacerbates bipolar disorder Ann Pharmacother undefined undefined-undefined
12345678